| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 265.88 Million | USD 1800.57 Million | 21.08% | 2024 |
FrequentlyAsked Questions
CRM197 is a non-toxic diphtheria toxin mutant that is used as a protein carrier for haptens and polysaccharides to make them immunogenic. Reportedly, the product is considered to be an ideal protein carrier and finds a slew of applications in approved conjugate vaccines that are used against encapsulated bacteria. Moreover, it is being assessed as a potential medicine-delivery fusion protein. In addition to this, CRM197 can also be utilized for preventing cancers having poor prognoses. It can be used in vaccines to make an individual immune to diseases such as pneumococcus, Haemophilus influenzae, and meningococcal meningitis.
The global CRM197 market is expected to grow due to rising demand for protein-based vaccines, increasing use in conjugate vaccine development, growth in immunization programs, and advancements in biopharmaceutical research.
According to a study, the global CRM197 market size was worth around USD 265.88 Million in 2024 and is expected to reach USD 1800.57 Million by 2034.
The global CRM197 market is expected to grow at a CAGR of 21.08% during the forecast period.
North America is expected to dominate the CRM197 market over the forecast period.
Leading players in the global CRM197 market include Xpress Biologics, Pfizer Inc., Fina Biosolutions LLC, Eubiologics, EirGenix Inc., Scarab Genomics, Beijing Kexing Biology Product, Ligand Pharmaceuticals, CanSino Biologic, among others.
The report explores crucial aspects of the CRM197 market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients